Pharnext Aktie
0,00EUR | 0,00EUR | -80,00% |
WKN DE: A400CX / ISIN: FR001400N1P4
Personal
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 30 | 22 | 20 | 16 | 6 |
Summe Anlagevermögen | 1 | 2 | 1 | 1 | 1 |
Summe Aktiva | 31 | 23 | 21 | 16 | 8 |
Bilanz (in Mio. EUR) - Passiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 47 | 24 | 21 | 22 | 23 |
Summe Fremdkapital | 57 | 30 | 34 | 34 | 41 |
Summe Eigenkapital | -26 | -7 | -13 | -18 | -33 |
Summe Passiva | 31 | 23 | 21 | 16 | 8 |
Adresse
14 rue de la République, 92150 Paris | |
Telefon | +33 (1) 41-09-22-30 |
Management
Gilbert Wagener
Chief Medical Officer |
Guy-Charles Fanneau de la Horie
Member-Supervisory Board |
Hugo Brugière
Manager |
James S. Kuo
Member-Supervisory Board |
Joshua Schafer
Chairman |
Lawrence J. Steinman
Member-Supervisory Board |
Raj Thota
Chief Manufacturing Officer |
Serguei Nabirotchkine
Vice President & Head-Systems Biology |